Gemvax&Kael announced their full-scale entry into the pharmaceutical industry through the acquisition of Samsung Pharmaceutical

Published: 2014-05-23 15:26:01

Updated: 2014-05-23 15:26:01

On May 22, Gemvax&Kael announced their full-scale entry into the pharmaceutical industry through the acquisition of Samsung Pharmaceutical Industry which is listed on the securities market. Gemvax&Kael is a parent company of Kaelgemvax which is developing the world's first anti-cancer vaccine for pancreatic cancer.

According to the company, Gemvax&Kael acquired 16.1% stake of Samsung Pharmaceu...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.